Evaluation of neutrophilic activity in patients submitted to kidney transplantation

Figures & data

TABLE 1.  Values of the arithmetic means and standard deviations of phagocytosis ingestion phase by neutrophils of renal transplant patients with cryoglobulinemia, without cryoglobulinemia, and healthy individuals: percentages of cells that presented three or more phagocytic vacuoles within a fixed number of 200 cells

Phagocytosis	CRYO+ (n = 28)	CRYO− (n = 9)	Healthy individuals (n = 37)
Zy (control assay) (%)	31.89 ± 8.37	28.78 ± 7.90	26.39 ± 6.38
Zy + homologous serum (%)	59.70 ± 7.00	67.13 ± 4.39	65.78 ± 4.18
Zy + autologous serum (%)	63.43 ± 8.14	68.89 ± 4.14	68.73 ± 4.58

Notes: CRYO+, patients with cryoglobulinemia; CRYO−, patients without cryoglobulinemia.

*p < 0.05 – statistically significant (Mann–Whitney test) between CRYO+ and CRYO– groups and CRYO+ and healthy individuals.

TABLE 2.  Values of the arithmetic means and standard deviations of the NBT test in renal transplant patients with cryoglobulinemia, without cryoglobulinemia, and healthy individuals

NBT	CRYO+ (n = 28)	CRYO− (n = 9)	Healthy individuals (n = 37)
Spontaneous (%)	6.71 ± 1.15	6.33 ± 1.12	7.08 ± 1.26
Stimulated (%)	14.39 ± 1.91	13.78 ± 2.22	14.65 ± 3.11

Notes: NBT, nitroblue tetrazolium; CRYO+, patients with cryoglobulinemia; CRYO−, patients without cryoglobulinemia.

p>0.05 – not statistically significant (Mann–Whitney test).

TABLE 3.  Values of the arithmetic means and standard deviations of the mean doses of immunosuppressive therapy in CRYO+ and CRYO− renal transplant patients

Immunosuppressive therapy	CRYO+	CRYO−
Cyclosporine (p = 0.142)	4.0 ± 1.5 (n = 21)	3.4 ± 0.52 (n = 7)
Tacrolimus (p = 0.262)	0.12 ± 0.01 (n = 5)	0.22 ± 0.13 (n = 3)
Mycophenolate mofetil (p = 0.477)	1.75 ± 0.29 (n = 6)	1.58 ± 0.38 (n = 4)
Azathioprine (p = 0.004)	1.65 ± 0.33 (n = 16)	1.98 ± 0.21 (n = 12)

Notes: CRYO+, patients with cryoglobulinemia; CRYO−, patients without cryoglobulinemia.

*p < 0.05 – statistically significant (unpaired Student's t-test).